Opthea Announces Leadership Change as Phase 3 Trials Near
Company Announcements

Opthea Announces Leadership Change as Phase 3 Trials Near

Opthea Limited (AU:OPT) has released an update.

Opthea Limited announced that Dr. Megan Baldwin will retire from its Board but will remain as Chief Innovation Officer, focusing on advancing the company’s innovation strategy. As Opthea gears up for pivotal Phase 3 data readouts for its lead product, sozinibercept, Dr. Baldwin’s continued leadership is seen as crucial. The company is also in the process of identifying a new board director to fill the upcoming vacancy.

For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskOpthea to Highlight Promising AMD Therapy at Key Events
TipRanks Australian Auto-Generated NewsdeskOpthea Limited to Present at Key November Investor Conferences
TipRanks Australian Auto-Generated NewsdeskOpthea Set to Highlight Innovations at Investor Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App